Cargando…

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab

Detalles Bibliográficos
Autores principales:	Smetanova, Jitka, Strizova, Zuzana, Sediva, Anna, Milota, Tomas, Horvath, Rudolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691856/ https://www.ncbi.nlm.nih.gov/pubmed/34957418 http://dx.doi.org/10.1016/S2665-9913(21)00393-3

Ejemplares similares

Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
por: Smetanova, Jitka, et al.
Publicado: (2022)

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients
por: Smetanova, Jitka, et al.
Publicado: (2022)

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
por: Malcova, Hana, et al.
Publicado: (2021)

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
por: Malcova, Hana, et al.
Publicado: (2021)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

Novel XIAP mutation causing enhanced spontaneous apoptosis and disturbed NOD2 signalling in a patient with atypical adult-onset Crohn’s disease
por: Parackova, Zuzana, et al.
Publicado: (2020)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies
por: Milota, Tomas, et al.
Publicado: (2023)

Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
por: Baker, Rahaf, et al.
Publicado: (2018)

COVID-19 in axial spondyloarthritis care provision: helping to straighten the long and winding road
por: Marzo-Ortega, Helena, et al.
Publicado: (2021)

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
por: Sun, Yuankai, et al.
Publicado: (2022)

Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds?
por: Klojdová, Iveta, et al.
Publicado: (2023)

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
por: Aparicio, María, et al.
Publicado: (2021)

Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab
por: Otsuka, Akiyo, et al.
Publicado: (2015)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
por: Ramonda, Roberta, et al.
Publicado: (2022)

Onset of spondyloarthritis in a patient treated with adalimumab for relapsing anterior uveitis – efficacy of secukinumab on the joint domain and on ocular inflammatory relapses: A case report
por: Raimondo, Vincenzo
Publicado: (2022)

O27 Recurrent severe uveitis treated with secukinumab following anti-TNF induced cutaneous vasculitis in a patient with axial spondyloarthritis
por: Chan, Antoni, et al.
Publicado: (2021)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
por: Ducourau, Emilie, et al.
Publicado: (2020)

Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA
por: Kaijasilta, Juha‐Pekka, et al.
Publicado: (2021)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial
por: Poddubnyy, Denis, et al.
Publicado: (2021)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
por: Dougados, Maxime, et al.
Publicado: (2023)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
por: Sieper, Joachim, et al.
Publicado: (2019)

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA
por: Milota, Tomas, et al.
Publicado: (2022)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA
por: Gaffney, Karl, et al.
Publicado: (2023)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort
por: Cantarini, Luca, et al.
Publicado: (2015)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Treat-to-Target in Axial Spondyloarthritis: Are we there yet?
por: Aouad, Krystel, et al.
Publicado: (2022)

Go or no-go for treat-to-target in axial spondyloarthritis?
por: Webers, Casper, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kde3immc5st8t5gdlqkikcgado